세계의 처방 피부과 치료제 시장 보고서(2025년)

Prescription Dermatological Drugs Global Market Report 2025

US $ 4,490 ￦ 6,183,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,938,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,692,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

처방 피부과 치료제 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 기간의 성장은 피부 질환의 유병률 증가, 피부과 건강에 대한 의식 증가, 피부과 진찰을 위한 원격 의료 도입 확대, 피부 관리 미용에 대한 수요 증가, 피부과 치료 보험 적용 강화, 맞춤형 의료와 정밀 피부과학에 대한 주목의 고조에 의해 초래될 것으로 예측됩니다.

피부질환의 유병률 증가는 처방 피부과 치료제 시장의 확대를 촉진할 것으로 예측됩니다. 이러한 질환의 증가는 주로 환경 오염 물질에 대한 노출 증가, 생활 방식의 변화, 스트레스 수준의 상승에 기인합니다. 처방 피부과 치료제는 증상을 완화하고 장기적인 피부 건강을 촉진하기 위한 표적 치료를 제공함으로써 이러한 증상을 관리하는데 중요한 역할을 하고 있습니다. Europe PubMed Central은 유럽 27개국에서 실시된 조사에서 약 1억 8,500만 명에 해당하는 참가자의 약 43.35%가 적어도 하나의 피부 질환을 경험하고 있으며, 진균 감염증, 아토피 피부염, 여드름이 가장 많은 것으로 보고되었습니다.

처방 피부과 치료제 시장의 주요 기업은 암메트 메디컬 요구에 대응하고 만성적이고 치료하기 어려운 피부 질환으로 고통받는 환자에게 효과적인 솔루션을 제공하기 위해 결절성 가려움증 치료법과 같은 혁신적인 치료법 개발을 우선합니다. 결절성 가려움증은 강한 가려움, 고조, 딱딱한 결절과 융기를 특징으로 하는 만성 피부 질환입니다. 미국 생명공학 기업인 Regeneron Pharmaceuticals Inc.는 프랑스 제약 기업인 Sanofi S.A.와 협력하여 미국 식품의약국(FDA)으로부터 듀피젠트(두필루맙) 승인을 획득했습니다. 이번 승인은 듀픽센트로 치료받은 환자의 가려움증 중증도와 피부 병변이 위약을 투여받은 환자에 비해 크게 개선된 임상시험 데이터를 기반으로 이루어졌습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 처방 피부과 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 처방 피부과 치료제 시장 : 성장률 분석
• 세계의 처방 피부과 치료제 시장 실적: 규모와 성장, 2019-2024년
• 세계의 처방 피부과 치료제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계의 처방 피부과 치료제 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 처방 피부과 치료제 시장 : 약제 클래스별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 코르티코스테로이드
• 레티노이드
• 칼시뉴린 억제제
• 항진균제
• 항생제
• 기타
• 세계의 처방 피부과 치료제 시장 : 적응증별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 여드름
• 건선
• 피부염
• 진균성 피부 감염증
• 기타
• 세계의 처방 피부과 치료제 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타
• 세계의 처방 피부과 치료제 시장 : 코르티코스테로이드별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 국소 코르티코스테로이드
• 경구 코르티코스테로이드
• 주사용 코르티코스테로이드
• 세계의 처방 피부과 치료제 시장 : 레티노이드별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 국소 레티노이드
• 경구 레티노이드
• 세계의 처방 피부과 치료제 시장 : 칼시뉴린 억제제별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 국소 칼시뉴린 억제제
• 경구 칼시뉴린 억제제
• 세계의 처방 피부과 치료제 시장 : 항진균제별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 국소 항진균제
• 경구 항진균제
• 세계의 처방 피부과 치료제 시장 : 항생 물질별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 국소 항생제
• 경구 항생제
• 세계의 처방 피부과 치료제 시장 : 기타 약제 클래스별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 면역억제제
• 광선요법제

제7장 지역별/국가별 분석

• 세계의 처방 피부과 치료제 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 처방 피부과 치료제 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 처방 피부과 치료제 시장 : 경쟁 구도
• 처방 피부과 치료제 시장 : 기업 프로파일
  • Pfizer Inc.
  • Johnson & Johnson
  • Merck KGaA
  • AbbVie Inc.
  • Bayer AG

제31장 기타 주요 기업 및 혁신 기업

• Novartis AG
• GSK plc
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Intas Pharmaceuticals Inc.
• Regeneron Pharmaceuticals Inc.
• Mylan NV
• Sun Pharmaceutical Industries Ltd.
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Zydus Cadila Health Care Limited
• Leo Pharma A/S
• Glenmark Pharmaceuticals Limited
• Almirall SA
• DermBiont Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

• 처방 피부과 치료제 시장, 2029년 : 새로운 기회를 제공하는 국가
• 처방 피부과 치료제 시장, 2029년 : 새로운 기회를 제공하는 부문
• 처방 피부과 치료제 시장, 2029년 : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

SHW

영문 목차

영문목차

Prescription dermatological drugs are medications prescribed by healthcare providers to treat various skin conditions, including acne, eczema, psoriasis, and other dermatological disorders. These drugs contain active ingredients that require medical supervision to ensure safe and effective use.

The primary drug classes of prescription dermatological drugs include corticosteroids, retinoids, calcineurin inhibitors, antifungal agents, antibiotics, and others. Corticosteroids, which are steroid hormones derived from the adrenal cortex or their synthetic analogs, are primarily used to reduce inflammation and suppress immune responses in various medical conditions. These medications are commonly prescribed for conditions such as acne, psoriasis, dermatitis, and fungal skin infections. They are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The prescription dermatological drugs market research report is one of a series of new reports from The Business Research Company that provides prescription dermatological drugs market statistics, including the prescription dermatological drugs industry's global market size, regional shares, competitors with a prescription dermatological drugs market share, detailed prescription dermatological drugs market segments, market trends and opportunities, and any further data you may need to thrive in the prescription dermatological drugs industry. This prescription dermatological drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The prescription dermatological drugs market size has grown strongly in recent years. It will grow from $37.77 billion in 2024 to $40.38 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to the increasing prevalence of skin disorders, greater awareness of skin health, the expansion of dermatology clinics, a growing geriatric population, rising healthcare expenditures, and increased investments in research and development.

The prescription dermatological drugs market size is expected to see strong growth in the next few years. It will grow to $52.27 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period is expected to be driven by the increasing prevalence of skin disorders, rising awareness of dermatological health, expanding telemedicine adoption for dermatology consultations, the growing demand for skincare aesthetics, enhanced insurance coverage for dermatological treatments, and the increasing focus on personalized medicine and precision dermatology. Key trends include the development of targeted biologic therapies, the adoption of gene editing for skin conditions, advancements in drug delivery systems, personalized treatments through genetic profiling, improved absorption in topical medications, and the integration of artificial intelligence to optimize drug formulations and treatment plans.

The growing prevalence of dermatological conditions is expected to drive the expansion of the prescription dermatological drugs market. Dermatological conditions encompass disorders affecting the skin, hair, or nails, such as eczema, psoriasis, and acne, which require medical treatment for effective symptom management. The increasing occurrence of these conditions is largely attributed to heightened exposure to environmental pollutants, lifestyle changes, and rising stress levels. Prescription dermatological drugs play a vital role in managing these conditions by providing targeted treatments to alleviate symptoms and promote long-term skin health. For example, in March 2022, Europe PubMed Central, a UK-based organization hosted by EMBL's European Bioinformatics Institute for biomedical research, reported that a study conducted across 27 European countries found that approximately 43.35% of participants equivalent to around 185 million individuals experienced at least one skin condition, with fungal infections, atopic dermatitis, and acne being the most prevalent. As a result, the increasing prevalence of dermatological conditions is fueling the growth of the prescription dermatological drugs market.

Leading companies in the prescription dermatological drugs market are prioritizing the development of innovative treatments, such as therapies for prurigo nodularis, to address unmet medical needs and provide more effective solutions for patients suffering from chronic and difficult-to-treat skin conditions. Prurigo nodularis is a chronic skin disorder characterized by intensely itchy, raised, and firm nodules or bumps on the skin. For instance, in September 2022, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, partnered with Sanofi S.A., a France-based pharmaceutical company, to secure approval from the U.S. Food and Drug Administration (FDA) for Dupixent (dupilumab). This marks the first and only FDA-approved treatment for prurigo nodularis. The approval was based on clinical trial data demonstrating significant improvements in itch severity and skin lesions in patients treated with Dupixent compared to those receiving a placebo.

In October 2024, Organon & Co., a US-based pharmaceutical company, acquired Dermavant Sciences Ltd. for $1.2 billion. Through this acquisition, Organon aims to expand its dermatology portfolio by incorporating innovative treatments for chronic skin conditions, including prurigo nodularis and psoriasis. Dermavant Sciences Ltd. is a US-based company specializing in the development of therapeutic solutions in immunodermatology.

Major players in the prescription dermatological drugs market are Pfizer Inc., Johnson & Johnson, Merck KGaA, AbbVie Inc., Bayer AG, Novartis AG, GSK plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Mylan NV, Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Zydus Cadila Health Care Limited, Leo Pharma A/S, Glenmark Pharmaceuticals Limited, Almirall S.A., DermBiont Inc.

North America was the largest region in the prescription dermatological drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in prescription dermatological drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prescription dermatological drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prescription dermatological drugs market consists of sales of products such as antifungals, antihistamines, and isotretinoin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prescription Dermatological Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prescription dermatological drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prescription dermatological drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prescription dermatological drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Corticosteroids; Retinoids; Calcineurin Inhibitors; Antifungal Agents; Antibiotics; Other Drug Classes
• 2) By Indication: Acne; Psoriasis; Dermatitis; Fungal Skin Infections; Other Indications
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Corticosteroids: Topical Corticosteroids; Oral Corticosteroids; Injectable Corticosteroids
• 2) By Retinoids: Topical Retinoids; Oral Retinoids
• 3) By Calcineurin Inhibitors: Topical Calcineurin Inhibitors; Oral Calcineurin Inhibitors
• 4) By Antifungal Agents: Topical Antifungals; Oral Antifungals
• 5) By Antibiotics: Topical Antibiotics; Oral Antibiotics
• 6) By Other Drug Classes: Immunosuppressants; Phototherapy Agents
• Companies Mentioned:Pfizer Inc.; Johnson & Johnson; Merck KGaA; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Prescription Dermatological Drugs Market Characteristics

3. Prescription Dermatological Drugs Market Trends And Strategies

4. Prescription Dermatological Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Prescription Dermatological Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Prescription Dermatological Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Prescription Dermatological Drugs Market Growth Rate Analysis
• 5.4. Global Prescription Dermatological Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Prescription Dermatological Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Prescription Dermatological Drugs Total Addressable Market (TAM)

6. Prescription Dermatological Drugs Market Segmentation

• 6.1. Global Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Retinoids
• Calcineurin Inhibitors
• Antifungal Agents
• Antibiotics
• Other Drug Classes
• 6.2. Global Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acne
• Psoriasis
• Dermatitis
• Fungal Skin Infections
• Other Indications
• 6.3. Global Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.4. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Corticosteroids
• Oral Corticosteroids
• Injectable Corticosteroids
• 6.5. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Retinoids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Retinoids
• Oral Retinoids
• 6.6. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Calcineurin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Calcineurin Inhibitors
• Oral Calcineurin Inhibitors
• 6.7. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Antifungal Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Antifungals
• Oral Antifungals
• 6.8. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Antibiotics
• Oral Antibiotics
• 6.9. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressants
• Phototherapy Agents

7. Prescription Dermatological Drugs Market Regional And Country Analysis

• 7.1. Global Prescription Dermatological Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Prescription Dermatological Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Prescription Dermatological Drugs Market

• 8.1. Asia-Pacific Prescription Dermatological Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Prescription Dermatological Drugs Market

• 9.1. China Prescription Dermatological Drugs Market Overview
• 9.2. China Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Prescription Dermatological Drugs Market

• 10.1. India Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Prescription Dermatological Drugs Market

• 11.1. Japan Prescription Dermatological Drugs Market Overview
• 11.2. Japan Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Prescription Dermatological Drugs Market

• 12.1. Australia Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Prescription Dermatological Drugs Market

• 13.1. Indonesia Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Prescription Dermatological Drugs Market

• 14.1. South Korea Prescription Dermatological Drugs Market Overview
• 14.2. South Korea Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Prescription Dermatological Drugs Market

• 15.1. Western Europe Prescription Dermatological Drugs Market Overview
• 15.2. Western Europe Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Prescription Dermatological Drugs Market

• 16.1. UK Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Prescription Dermatological Drugs Market

• 17.1. Germany Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Prescription Dermatological Drugs Market

• 18.1. France Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Prescription Dermatological Drugs Market

• 19.1. Italy Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Prescription Dermatological Drugs Market

• 20.1. Spain Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Prescription Dermatological Drugs Market

• 21.1. Eastern Europe Prescription Dermatological Drugs Market Overview
• 21.2. Eastern Europe Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Prescription Dermatological Drugs Market

• 22.1. Russia Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Prescription Dermatological Drugs Market

• 23.1. North America Prescription Dermatological Drugs Market Overview
• 23.2. North America Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Prescription Dermatological Drugs Market

• 24.1. USA Prescription Dermatological Drugs Market Overview
• 24.2. USA Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Prescription Dermatological Drugs Market

• 25.1. Canada Prescription Dermatological Drugs Market Overview
• 25.2. Canada Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Prescription Dermatological Drugs Market

• 26.1. South America Prescription Dermatological Drugs Market Overview
• 26.2. South America Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Prescription Dermatological Drugs Market

• 27.1. Brazil Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Prescription Dermatological Drugs Market

• 28.1. Middle East Prescription Dermatological Drugs Market Overview
• 28.2. Middle East Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Prescription Dermatological Drugs Market

• 29.1. Africa Prescription Dermatological Drugs Market Overview
• 29.2. Africa Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Prescription Dermatological Drugs Market Competitive Landscape And Company Profiles

• 30.1. Prescription Dermatological Drugs Market Competitive Landscape
• 30.2. Prescription Dermatological Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Prescription Dermatological Drugs Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. GSK plc
• 31.3. Amgen Inc.
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Intas Pharmaceuticals Inc.
• 31.6. Regeneron Pharmaceuticals Inc.
• 31.7. Mylan NV
• 31.8. Sun Pharmaceutical Industries Ltd.
• 31.9. Cipla Limited
• 31.10. Dr. Reddy's Laboratories Ltd.
• 31.11. Zydus Cadila Health Care Limited
• 31.12. Leo Pharma A/S
• 31.13. Glenmark Pharmaceuticals Limited
• 31.14. Almirall S.A.
• 31.15. DermBiont Inc.

32. Global Prescription Dermatological Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prescription Dermatological Drugs Market

34. Recent Developments In The Prescription Dermatological Drugs Market

35. Prescription Dermatological Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Prescription Dermatological Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Prescription Dermatological Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Prescription Dermatological Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료